当前位置:首页 >财报库 > 中译版报告详情

嘉德诺Cardinal Health(CAH)2023财年第二季度财报(中译版)(15页).pdf

上传人: Kell****reet 编号:134429 2023-07-28 15页 1.61MB

下载:

1、Exhibit 99.1 FOR IMMEDIATE RELEASE Cardinal Health Reports Second Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance Revenue increased 13%to$51.5 billion GAAP1 operating loss was$119 million due to a non-cash,pre-tax goodwill impairment of$709 million related to the M

2、edical segment;GAAP diluted loss per share was$0.50 Non-GAAP operating earnings of$467 million were in-line with the second quarter of last year;non-GAAP diluted EPS increased 4%to$1.32 Fiscal year 2023 non-GAAP EPS guidance raised to$5.20 to$5.50,from$5.05 to$5.40 DUBLIN,Ohio,February 2,2023 Cardin

3、al Health(NYSE:CAH)today reported second quarter fiscal year 2023 revenues of$51.5 billion,an increase of 13%from the second quarter of fiscal year 2022.Second quarter GAAP operating loss was$119 million due to a non-cash,pre-tax goodwill impairment of$709 million related to the Medical segment.GAAP

4、 diluted loss per share was$0.50,primarily due to this impairment,net of tax effects.Second quarter non-GAAP operating earnings of$467 million were in-line with the second quarter of last year.Non-GAAP diluted earnings per share(EPS)increased 4%to$1.32,due to lower interest expense and a lower share

5、 count,partially offset by a higher non-GAAP effective tax rate.Our second quarter results demonstrate continued momentum against our plans,led by better-than-expected performance in the Pharmaceutical segment and Medical results in-line with our prior commentary,”said Jason Hollar,CEO of Cardinal H

6、ealth.With the first half of fiscal year 2023 behind us,we are pleased to raise our full year non-GAAP EPS guidance and outlook for the Pharmaceutical segment.In the Medical segment,we remain confident in our Medical Improvement Plan,including the actions we are taking to mitigate supply chain infla

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Cardinal Health发布了2023财年第二季度财报,总收入增长13%至515亿美元。其中,制药部门收入增长15%至477亿美元,医疗部门收入下降7%至38亿美元。GAAP营业亏损为1.19亿美元,主要由于医疗部门7.09亿美元的商誉减值损失。非GAAP营业收益为4.67亿美元,与去年同期持平。非GAAP每股摊薄收益为1.32美元,同比增长4%。公司提高了2023财年非GAAP每股收益预期至5.20至5.50美元,高于之前的5.05至5.40美元。
医疗部门商誉减值对卡迪纳尔健康的影响是什么? 非GAAP每股收益提高的原因是什么? 医疗部门的业绩为何出现下滑?
客服
商务合作
小程序
服务号
折叠